Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

NCT04849351 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Marginal Zone Lymphoma
Follicular Lymphoma

Interventions

DRUG: HMPL-689

Sponsor

Hutchison Medipharma Limited